Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

• Published in: Kidney international Vol. 68; no. 4; pp. 1793 - 1800
• Main Authors: Cunningham, John, Danese, Mark, Olson, Kurt, Klassen, Preston, Chertow, Glenn M.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.10.2005; Nature Publishing; Elsevier Limited
• Subjects: Adult; Aged; Biological and medical sciences; calcimimetics; Cardiovascular Diseases - mortality; cinacalcet; Cinacalcet Hydrochloride; Endocrinopathies; Female; Fractures, Bone - mortality; Humans; Hyperparathyroidism, Secondary - drug therapy; Hyperparathyroidism, Secondary - mortality; Kidney Failure, Chronic - mortality; Male; Medical sciences; Middle Aged; Naphthalenes - administration & dosage; Naphthalenes - adverse effects; Nephrology. Urinary tract diseases; Non tumoral diseases. Target tissue resistance. Benign neoplasms; outcomes; Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases); PTH; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; secondary hyperparathyroidism; cinacalcet; secondary hyperparathyroidism; outcomes; PTH; calcimimetics; Endocrinopathy; Secondary; Nephrology; Prognosis; Diseases of the osteoarticular system; Cardiovascular disease; Fracture; Trauma; Urology; Health-Related Quality of Life; Parathormone; Parathyroid hormone; Parathyroid diseases; Cinacalcet; Hyperparathyroidism

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Secondary hyperparathyroidism (HPT) and abnormal mineral metabolism are thought to play an important role in bone and cardiovascular disease in patient...